Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CodaVax-RSV in Seropositive and Seronegative Children
NCT04919109Phase 1Terminated
- Sponsor
- Codagenix
- Start
- Mar 2023
- Primary completion
- Jun 2025
- Modality
- Live Attenuated Vaccines
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of codavax-rsv in respiratory syncytial virus infection (RSV) (5 arms), sponsored by Codagenix. Primary endpoints: Number of participants reporting expected adverse reactions at Day 7, Number of participant reported adverse events at Day 57 and 1 more. Started Mar 2023; status: terminated.
02
Drugs
codavax-rsv
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT04919109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04919109.